Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Clinical Requirements Regarding In Silico Oncology

Bookmark and Share
Published: 23 Jan 2009
Views: 11532
Rating:
Save
Professor Norbert Graf, Director of Oncology and Haematology Clinic, University of Saarland
Lecture from the European Union ICT BIO 2008 Conference (Oct. 23-24, 2008) on Clinical Requirements Regarding In Silico Oncology

Related Videos

ZUMA-7: Axi-cel is superior to standard of care across common prognostic...
Dr Fred Locke - Moffitt Cancer Center, Tampa, USA
ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )
23 Dec 2022
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of...
Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL ( Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA )
21 Dec 2022
PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival...
Dr Monzr Al Malki - City of Hope, Duarte, USA
PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival compared to Tac/MTX in graft-versus-host disease  ( Dr Monzr Al Malki - City of Hope, Duarte, USA )
21 Dec 2022
Effective treatment of low risk acute GVHD with itacitinib monotherapy
Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA
Effective treatment of low risk acute GVHD with itacitinib monotherapy ( Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA )
21 Dec 2022
Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic...
Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA
Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )
19 Dec 2022
Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients...
Dr Abdulraheem Yacoub - University of Kansas Cancer Center, Kansas City, USA
Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients having a suboptimal response to ruxolitinib ( Dr Abdulraheem Yacoub - University of Kansas Cancer Center, Kansas City, USA )
19 Dec 2022
Consolidation therapy with blinatumomab improves OS in newly diagnosed patients...
Dr Mark Litzow - Mayo Clinic, Rochester, USA
Consolidation therapy with blinatumomab improves OS in newly diagnosed patients with B-Lineage ALL in MRD negative remission ( Dr Mark Litzow - Mayo Clinic, Rochester, USA )
19 Dec 2022
PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning
Dr Shernan Holtan - University of Minnesota, Minneapolis, USA
PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning ( Dr Shernan Holtan - University of Minnesota, Minneapolis, USA )
15 Dec 2022
Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response...
Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA
Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease ( Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA )
15 Dec 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation